The company's product pipeline includes ALVR106, ALVR109, ALVR108, and others, with Viralym-M being a multi-VST therapy targeting five viruses. AlloVir's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company's manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. AlloVir is advancing multiple mid- and late-stage clinical trials across its product portfolio, with its headquarters located in Houston, Texas.